Superbug crept through NIH hospital last year – killing six

As a deadly infection, untreatable by nearly every antibiotic, spread through the National Institutes of Health’s Clinical Center last year, the staff resorted to extreme measures. They built a wall to isolate patients, gassed rooms with vaporized disinfectant and even ripped out plumbing. They eventually used rectal swabs to test every patient in the 234-bed hospital.

Still, for six months, as physicians fought to save the infected, the bacteria spread, eventually reaching 17 gravely ill patients. Eleven died, six from bloodstream superbug infections.

The outbreak of the antibiotic-resistant bacteria known as Klebsiella pneumoniae was not made public until Wednesday, when NIH researchers published a scientific paper describing the advanced genetic technology they deployed to trace the outbreak.

This was “the proverbial superbug that we’ve all worried about for a long time,” said Tara Palmore, an infection control specialist at the Bethesda hospital.

With some 99,000 U.S. deaths attributed to hospital-borne infections annually, the NIH outbreak provides a stark case study of the dangers of the latest wave of hospital-bred bacteria and the extreme measures hospitals must adopt to stem the rising superbug tide.

The NIH Clinical Center now screens every patient transferring from another facility for superbugs, tests every patient in the intensive care unit twice a week and screens every patient monthly…

This was our introduction to [antibiotic-resistant] Klebsiella,” Palmore said. “We hoped we would never see it…”

Nationwide, about 6 percent of hospitals are battling outbreaks of the class of superbugs known as carbapenem-resistant bacteria, which includes Klebsiella, said Alexander Kallen of the CDC. These bacteria usually live harmlessly in our intestinal tracts, and they pose little or no threat to patients with healthy immune systems. But in patients with compromised immune systems, the bacteria can turn dangerous, gaining an enzyme that defeats even the most powerful antibiotics. That’s what happened at NIH.

The six patients who died of bloodstream Klebsiella infections had immune systems weakened by cancer, anti-rejection drugs given after organ transplants, and genetic disorders.

The CDC detected this type of antibiotic-resistant bacteria in 2000. “Since then, we’ve seen it spread across the country,” Kallen said, to 41 states.

Please read the whole article. Read the details of a wartime siege against this superbug. Understand why fiscal and political support is always needed to back up efforts by the NIH and CDC to muster programmatic assaults on disease vectors that can burn through a hospital population.

What took place in this hospital wasn’t that dramatic in terms of numbers – but, no less fatal and horrifying to the victims, to the friends and relatives of affected patients and staff. Please understand that what science we have at hand may not be sufficient, what public health procedures we presently enforce may be inadequate – only the dedication of more talent and funds will aid the fight against superbugs like this.

Thanks, Corn

2 comments

  1. On&On&On

    The manufacturer of the gastrointestinal endoscopes that spread a drug-resistant “superbug” at U.S. hospitals, including UCLA, where two patients have died, was selling them without federal permission to do so, according to the Food and Drug Administration. http://www.mcall.com/news/breaking/mc-olympus-scopes-super-bug-20150304-story.html#page=1 Olympus started selling its TJF-Q180V duodenoscope in 2010, but the FDA didn’t notice until late 2013 or early 2014 that the company had never asked for clearance to put it on the market, according to CNN, which attributed the information to Karen Riley, deputy director of strategy for the FDA’s Office of External Affairs.
    “Why didn’t we notice it? I don’t know,” Riley said.
    Olympus could not be immediately reached for comment.
    The deadly outbreaks came after years of red flags. And government officials now concede the problem may be even worse because many scope-related infections have gone undetected or unreported.
    Since 2007, ECRI Institute, a nonprofit group that evaluates medical devices for hospitals and other organizations, has listed the risk of contaminated endoscopes and other surgical instruments among its top 10 health hazards.
    In 2008, the U.S. Centers for Disease Control and Prevention urged that endoscopes be redesigned so they don’t represent a “potential source of infectious agents.”
    Last year, the Joint Commission, which accredits and inspects hospitals, raised alarms about tainted endoscopes and other equipment posing an immediate threat to patients’ lives.
    The FDA said it has received 75 reports of contaminated scopes causing possible infections in 135 patients who underwent endoscopic retrograde cholangiopancreatography, or ERCP, from January 2013 to December 2014.
    The carbapenem-resistant Enterobacteriaceae superbug that was shared on the scopes at UCLA and in other outbreaks can be fatal in up to 50 percent of patients who become infected.
    In April 2012, Olympus put a new focus on its medical business to overcome the ongoing fallout from a $1.7-billion accounting scandal. “Two years ago, Olympus was in a state of crisis,” Hiroyuki Sasa, the company’s president, said in the 2014 Olympus annual report. He hailed the medical business for a “record-breaking performance.”
    One key part of that success has been the company’s close ties to doctors, industry analysts say.
    Olympus is a major donor to the American Society for Gastrointestinal Endoscopy. The company also contributed more than $1 million to the society’s new Institute for Training and Technology. The company’s relationship with medical providers has already come under scrutiny. Last month, Olympus said federal investigators are looking into whether it violated laws that ban improper kickbacks to doctors and other customers. The company said it’s working to resolve the matter.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s